Sub-toxic cisplatin concentrations induce extensive chromosomal, nuclear and nucleolar abnormalities associated with high malignancy before acquired resistance develops: Implications for clinical caution

HeLa cells subjected to increasing concentrations of sub-toxic cisplatin exhibited large-scale, multiple-type abnormalities in nuclei, nucleoli, chromosomes, and chromosomal numbers, indicating genetic/chromosomal instability associated with high malignancy, before the development of cisplatin resistance. These results suggest that low doses of cisplatin administration in the clinical setting may promote malignancy and caution should be used with this type of treatment.

Authors

Institutions

Publication Details

Journal
PLoS ONE
Published
2024-12-26
DOI
https://doi.org/10.1371/journal.pone.0311976
Citations
1
Primary Topic
Chemotherapy-induced organ toxicity mitigation
Type
article
Field-Weighted Citation Impact
0.42
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Sub-toxic cisplatin concentrations induce extensive chromosomal, nuclear and nucleolar abnormalities associated with high malignancy before acquired resistance develops: Implications for clinical caution

George Koumakis, Robert M. Hoffman, George J. Delinasios, John G. Delinassios et al.
1 citations
PLoS ONE
Chemotherapy-induced organ toxicity mitigation
0.42
article

Sub-toxic cisplatin concentrations induce extensive chromosomal, nuclear and nucleolar abnormalities associated with high malignancy before acquired resistance develops: Implications for clinical caution

George Koumakis, Robert M. Hoffman, George J. Delinasios, John G. Delinassios, Dimitrios Palitskaris, Kyriaki-Nefelli Poulatsidou
article en
1 citations

Abstract

HeLa cells subjected to increasing concentrations of sub-toxic cisplatin exhibited large-scale, multiple-type abnormalities in nuclei, nucleoli, chromosomes, and chromosomal numbers, indicating genetic/chromosomal instability associated with high malignancy, before the development of cisplatin resistance. These results suggest that low doses of cisplatin administration in the clinical setting may promote malignancy and caution should be used with this type of treatment.

PLoS ONEVol. 19(12)
University of California San Diego (US), AntiCancer (United States) (US)
Good health and well-being
Openalex Percentile: Top 31%
Chemotherapy-induced organ toxicity mitigation
0.42
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.